Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 201

1.

Cost-Effectiveness of the Screening for the Primary Prevention of Fragility Hip Fracture in Spain Using FRAX®.

Martin-Sanchez M, Comas M, Posso M, Louro J, Domingo L, Tebé C, Castells X, Espallargues M.

Calcif Tissue Int. 2019 Jun 6. doi: 10.1007/s00223-019-00570-9. [Epub ahead of print]

PMID:
31172231
2.

Changes in mammographic density over time and the risk of breast cancer: An observational cohort study.

Román M, Sala M, Baré M, Posso M, Vidal C, Louro J, Sánchez M, Peñalva L, Castells X; BELE study group.

Breast. 2019 May 13;46:108-115. doi: 10.1016/j.breast.2019.04.007. [Epub ahead of print]

PMID:
31132476
3.

Correction to: Health care services use among long-term breast cancer survivors: a systematic review.

Jansana A, Posso M, Guerrero I, Prados-Torres A, Del Cura MI, Castells X, Sala M.

J Cancer Surviv. 2019 Jun;13(3):494. doi: 10.1007/s11764-019-00763-z.

PMID:
31131425
4.

A systematic review and quality assessment of individualised breast cancer risk prediction models.

Louro J, Posso M, Hilton Boon M, Román M, Domingo L, Castells X, Sala M.

Br J Cancer. 2019 May 22. doi: 10.1038/s41416-019-0476-8. [Epub ahead of print]

PMID:
31114019
5.

Health care services use among long-term breast cancer survivors: a systematic review.

Jansana A, Posso M, Guerrero I, Prados-Torres A, Del Cura MI, Castells X, Sala M.

J Cancer Surviv. 2019 Jun;13(3):477-493. doi: 10.1007/s11764-019-00755-z. Epub 2019 Apr 9. Review. Erratum in: J Cancer Surviv. 2019 May 27;:.

PMID:
30968367
6.

Mammographic breast density: How it affects performance indicators in screening programmes?

Posso M, Louro J, Sánchez M, Román M, Vidal C, Sala M, Baré M, Castells X; BELE study group.

Eur J Radiol. 2019 Jan;110:81-87. doi: 10.1016/j.ejrad.2018.11.012. Epub 2018 Nov 15.

PMID:
30599878
7.

Risk of hospital readmission and associated factors after a positive sample for a multidrug-resistant microorganism.

Sentís A, González C, Montero M, Herranz M, Hidalgo C, Campà C, Sala M, Macià F, Román M, Prats-Uribe A, Horcajada JP, Castells X.

Eur J Public Health. 2018 Dec 24. doi: 10.1093/eurpub/cky262. [Epub ahead of print]

PMID:
30590519
8.

Long-term risk of screen-detected and interval breast cancer after false-positive results at mammography screening: joint analysis of three national cohorts.

Román M, Hofvind S, von Euler-Chelpin M, Castells X.

Br J Cancer. 2019 Jan;120(2):269-275. doi: 10.1038/s41416-018-0358-5. Epub 2018 Dec 19.

PMID:
30563993
9.

External validation of the PREDICT tool in Spanish women with breast cancer participating in population-based screening programmes.

Aguirre U, García-Gutiérrez S, Romero A, Domingo L, Castells X, Sala M; CAMISS Study Group.

J Eval Clin Pract. 2018 Dec 12. doi: 10.1111/jep.13084. [Epub ahead of print]

PMID:
30548721
10.

Changes in FIT values below the threshold of positivity and short-term risk of advanced colorectal neoplasia: Results from a population-based cancer screening program.

Buron A, Román M, Augé JM, Macià F, Grau J, Sala M, Louro J, Martinez-Alonso M, Alvarez-Urturi C, Andreu M, Bessa X, Zaffalon D, Castells A, Pellisé M, Aldea M, Rivero L, Hernández C, Torá-Rocamora I, Castells X.

Eur J Cancer. 2019 Jan;107:53-59. doi: 10.1016/j.ejca.2018.11.004. Epub 2018 Dec 10.

PMID:
30544059
11.

Variability of breast surgery in women participating in breast cancer screening programs.

Blay L, Louro J, Barata T, Baré M, Ferrer J, Abad JM, Castells X, Sala M.

Cir Esp. 2019 Feb;97(2):89-96. doi: 10.1016/j.ciresp.2018.11.001. Epub 2018 Dec 9. English, Spanish.

PMID:
30541660
12.

Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical look.

Faltinsen E, Zwi M, Castells X, Gluud C, Simonsen E, Storebø OJ.

BMJ Evid Based Med. 2019 Jun;24(3):99-102. doi: 10.1136/bmjebm-2018-111110. Epub 2018 Dec 10. No abstract available.

PMID:
30530806
13.

Population-based colorectal cancer screening: Interval cancers and relationship with the quantitative faecal immunological for hemoglobin.

Burón A, Macià F, Andreu M, Pellisé M, Castells X, Grau J.

Med Clin (Barc). 2019 Apr 18;152(8):303-306. doi: 10.1016/j.medcli.2018.06.022. Epub 2018 Aug 23. English, Spanish.

PMID:
30146355
14.

Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.

Castells X, Blanco-Silvente L, Cunill R.

Cochrane Database Syst Rev. 2018 Aug 9;8:CD007813. doi: 10.1002/14651858.CD007813.pub3.

PMID:
30091808
15.

Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer's disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients.

Blanco-Silvente L, Capellà D, Garre-Olmo J, Vilalta-Franch J, Castells X.

BMC Geriatr. 2018 Jul 24;18(1):168. doi: 10.1186/s12877-018-0857-5.

16.

[Social and clinical determinants of the use of health services in women with breast cancer (Cohort DAMA)].

Puigpinós-Riera R, Castillo Gómez A, Romero Morales A, Aller M, Castells X, Sala M; grupo Cohort Dama.

Gac Sanit. 2018 Jul 18. pii: S0213-9111(18)30111-0. doi: 10.1016/j.gaceta.2018.04.014. [Epub ahead of print] Spanish.

17.

Survival and Disease-Free Survival by Breast Density and Phenotype in Interval Breast Cancers.

Sala M, Domingo L, Louro J, Torá-Rocamora I, Baré M, Ferrer J, Carmona-Garcia MC, Barata T, Román M, Macià F, Castells X; CAMISS Study Group.

Cancer Epidemiol Biomarkers Prev. 2018 Aug;27(8):908-916. doi: 10.1158/1055-9965.EPI-17-0995. Epub 2018 May 31.

PMID:
29853482
18.

[Analysis of drug-related problems in a tertiary university hospital in Barcelona (Spain)].

Ferrández O, Casañ B, Grau S, Louro J, Salas E, Castells X, Sala M.

Gac Sanit. 2018 May 7. pii: S0213-9111(18)30043-8. doi: 10.1016/j.gaceta.2018.01.002. [Epub ahead of print] Spanish.

19.

Meat intake, methods and degrees of cooking and breast cancer risk in the MCC-Spain study.

Boldo E, Castelló A, Aragonés N, Amiano P, Pérez-Gómez B, Castaño-Vinyals G, Martín V, Guevara M, Urtiaga C, Dierssen-Sotos T, Fernández-Tardón G, Moreno V, Solans M, Peiró R, Capelo R, Gómez-Acebo I, Castilla J, Molina AJ, Castells X, Altzibar JM, Lope V, Kogevinas M, Romieu I, Pollán M; MCC-Spain researchers.

Maturitas. 2018 Apr;110:62-70. doi: 10.1016/j.maturitas.2018.01.020. Epub 2018 Jan 31.

PMID:
29563037
20.

Clinical and histologic characteristics of breast cancers in women with previous pathologic diagnosis of benign breast disease in Spain.

Román M, Caicoya M, Espinàs J, Sala M, Torá-Rocamora I, Quinta MJ, Vernet M, Saladié F, Romero A, Sánchez M, Baré M, Vidal C, Servitja S, Natal C, Corominas J, Ferrer J, Rodríguez-Arana A, Castells X; BELE Project study group.

Breast J. 2018 Jul;24(4):509-518. doi: 10.1111/tbj.13003. Epub 2018 Mar 8.

PMID:
29517151
21.

Health services research in patients with breast cancer (CAMISS-prospective): study protocol for an observational prospective study.

García-Gutierrez S, Orive M, Sarasqueta C, Legarreta MJ, Gonzalez N, Redondo M, Rivero A, Serrano-Aguilar P, Castells X, Quintana JM, Sala M; REDISSEC-CaMISS group.

BMC Cancer. 2018 Jan 8;18(1):54. doi: 10.1186/s12885-017-3926-9.

22.

Adherence to follow-up in high-risk adenoma patients diagnosed by, and excluded from the Barcelona colorectal cancer screening programme.

Otero I, Burón A, Macià F, Álvarez-Urturi C, Comas M, Román M, Castells X; en nombre del Grupo Procolon.

Gastroenterol Hepatol. 2018 Apr;41(4):226-233. doi: 10.1016/j.gastrohep.2017.11.010. Epub 2017 Dec 31. English, Spanish.

PMID:
29295752
23.

Measuring anticholinergic exposure in patients with dementia: A comparative study of nine anticholinergic risk scales.

Turró-Garriga O, Calvó-Perxas L, Vilalta-Franch J, Blanco-Silvente L, Castells X, Capellà D, Garre-Olmo J; Registry of Dementia of Girona Study Group (ReDeGi Study Group).

Int J Geriatr Psychiatry. 2018 May;33(5):710-717. doi: 10.1002/gps.4844. Epub 2018 Jan 2.

PMID:
29292848
24.

Summary statement on screening for prostate cancer in Europe.

Heijnsdijk EAM, Bangma CH, Borràs JM, de Carvalho TM, Castells X, Eklund M, Espinàs JA, Graefen M, Grönberg H, Lansdorp-Vogelaar I, Leeuwen PJV, Nelen V, Recker F, Roobol MJ, Vandenbulcke P, de Koning HJ.

Int J Cancer. 2018 Feb 15;142(4):741-746. doi: 10.1002/ijc.31102. Epub 2017 Oct 25.

25.

The effect of information about the benefits and harms of mammography on women's decision-making: study protocol for a randomized controlled trial.

Carles M, Martínez-Alonso M, Pons A, Pérez-Lacasta MJ, Perestelo-Pérez L, Sala M, Vidal C, Garcia M, Toledo-Chávarri A, Codern N, Feijoo-Cid M, Romero A, Pla R, Soler-González J, Castells X, Rué M; InforMa Group.

Trials. 2017 Sep 12;18(1):426. doi: 10.1186/s13063-017-2161-7.

26.

The Impact of Incident Disclosure Behaviors on Medical Malpractice Claims.

Giraldo P, Sato L, Castells X.

J Patient Saf. 2017 Jun 30. doi: 10.1097/PTS.0000000000000342. [Epub ahead of print]

PMID:
28671905
27.

Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients.

Riera M, Castells X, Tobias A, Cunill R, Blanco L, Capellà D.

Psychopharmacology (Berl). 2017 Sep;234(17):2657-2671. doi: 10.1007/s00213-017-4662-1. Epub 2017 Jun 19.

PMID:
28631099
28.

Association between socioeconomic deprivation and colorectal cancer screening outcomes: Low uptake rates among the most and least deprived people.

Buron A, Auge JM, Sala M, Román M, Castells A, Macià F, Comas M, Guiriguet C, Bessa X, Castells X; and the PROCOLON research group.

PLoS One. 2017 Jun 16;12(6):e0179864. doi: 10.1371/journal.pone.0179864. eCollection 2017.

29.

Impact of comorbidity on survival by tumour location: Breast, colorectal and lung cancer (2000-2014).

Parés-Badell O, Banqué M, Macià F, Castells X, Sala M.

Cancer Epidemiol. 2017 Aug;49:66-74. doi: 10.1016/j.canep.2017.05.010. Epub 2017 Jun 3.

PMID:
28586708
30.

A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events.

Faillie JL, Ferrer P, Gouverneur A, Driot D, Berkemeyer S, Vidal X, Martínez-Zapata MJ, Huerta C, Castells X, Rottenkolber M, Schmiedl S, Sabaté M, Ballarín E, Ibáñez L.

J Clin Epidemiol. 2017 Jun;86:168-175. doi: 10.1016/j.jclinepi.2017.04.023. Epub 2017 May 6.

PMID:
28487158
31.

Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case-control study.

Posso M, Corominas JM, Serrano L, Román M, Torá-Rocamora I, Domingo L, Romero A, Quintana MJ, Vernet-Tomas M, Baré M, Vidal C, Sánchez M, Saladié F, Natal C, Ferrer J, Servitja S, Sala M, Castells X; BELE Study Group.

Cancer Med. 2017 Jun;6(6):1482-1489. doi: 10.1002/cam4.1080. Epub 2017 May 4.

32.

Incremental cost of nosocomial bacteremia according to the focus of infection and antibiotic sensitivity of the causative microorganism in a university hospital.

Riu M, Chiarello P, Terradas R, Sala M, Garcia-Alzorriz E, Castells X, Grau S, Cots F.

Medicine (Baltimore). 2017 Apr;96(17):e6645. doi: 10.1097/MD.0000000000006645.

33.

Cumulative risk of breast cancer screening outcomes according to the presence of previous benign breast disease and family history of breast cancer: supporting personalised screening.

Román M, Quintana MJ, Ferrer J, Sala M, Castells X.

Br J Cancer. 2017 May 23;116(11):1480-1485. doi: 10.1038/bjc.2017.107. Epub 2017 Apr 20.

34.

Cost and detection rate of glaucoma screening with imaging devices in a primary care center.

Anton A, Fallon M, Cots F, Sebastian MA, Morilla-Grasa A, Mojal S, Castells X.

Clin Ophthalmol. 2017 Feb 16;11:337-346. doi: 10.2147/OPTH.S120398. eCollection 2017.

35.

Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients.

Blanco-Silvente L, Castells X, Saez M, Barceló MA, Garre-Olmo J, Vilalta-Franch J, Capellà D.

Int J Neuropsychopharmacol. 2017 Jul 1;20(7):519-528. doi: 10.1093/ijnp/pyx012. Review.

36.

Corrigendum: Modelling mutational landscapes of human cancers in vitro.

Olivier M, Weninger A, Ardin M, Huskova H, Castells X, Vallée MP, McKay J, Nedelko T, Muehlbauer KR, Marusawa H, Alexander J, Hazelwood L, Byrnes G, Hollstein M, Zavadil J.

Sci Rep. 2017 Jan 16;7:40898. doi: 10.1038/srep40898. No abstract available.

37.

Effectiveness and safety of drugs used for stroke prevention in a cohort of non-valvular atrial fibrillation patients from a primary care electronic database.

Giner-Soriano M, Roso-Llorach A, Vedia Urgell C, Castells X, Capellà D, Ferreira-González I, Elorza-Ricart JM, Casajuana M, Troncoso Mariño A, Diògene E, Bolíbar B, Violan C, Morros R.

Pharmacoepidemiol Drug Saf. 2017 Jan;26(1):97-107. doi: 10.1002/pds.4137. Epub 2016 Nov 20. Erratum in: Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):1011.

PMID:
27868275
38.

Long-Term Prediction of the Demand of Colonoscopies Generated by a Population-Based Colorectal Cancer Screening Program.

Comas M, Mendivil J, Andreu M, Hernández C, Castells X.

PLoS One. 2016 Oct 12;11(10):e0164666. doi: 10.1371/journal.pone.0164666. eCollection 2016.

39.

Psychostimulant drugs for cocaine dependence.

Castells X, Cunill R, Pérez-Mañá C, Vidal X, Capellà D.

Cochrane Database Syst Rev. 2016 Sep 27;9:CD007380. doi: 10.1002/14651858.CD007380.pub4. Review.

40.

Prevalence of persistent pain after breast cancer treatment by detection mode among participants in population-based screening programs.

Romero A, Torà-Rocamora I, Baré M, Barata T, Domingo L, Ferrer J, Torà N, Comas M, Merenciano C, Macià F, Castells X, Sala M; CAMISS Study Group.

BMC Cancer. 2016 Sep 15;16(1):735. doi: 10.1186/s12885-016-2768-1.

41.

Eleven-year descriptive analysis of closed court verdicts on medical errors in Spain and Massachusetts.

Giraldo P, Sato L, Martínez-Sánchez JM, Comas M, Dwyer K, Sala M, Castells X.

BMJ Open. 2016 Aug 30;6(8):e011644. doi: 10.1136/bmjopen-2016-011644.

42.

Predicting the Burden of Revision Knee Arthroplasty: Simulation of a 20-Year Horizon.

Guerrero-Ludueña RE, Comas M, Espallargues M, Coll M, Pons M, Sabatés S, Allepuz A, Castells X.

Value Health. 2016 Jul-Aug;19(5):680-7. doi: 10.1016/j.jval.2016.02.018. Epub 2016 Apr 23.

43.

The treatment of dual ADHD: a drop in the ocean.

Cunill R, Castells X.

Adicciones. 2016 Jun 15;28(3):131-5. doi: 10.20882/adicciones.836. English, Spanish.

44.

Analysis of participant satisfaction in the Barcelona colorectal cancer screening programme: Positive evaluation of the community pharmacy.

Burón A, Posso M, Sivilla J, Grau J, Guayta R, Castells X, Castells A, Macià F; en nombre del Grupo Procolon.

Gastroenterol Hepatol. 2017 Apr;40(4):265-275. doi: 10.1016/j.gastrohep.2016.04.015. Epub 2016 Jun 10. English, Spanish.

PMID:
27292268
45.

Minimum intravenous thrombolysis utilization rates in acute ischemic stroke to achieve population effects on disability: A discrete-event simulation model.

Hoffmeister L, Lavados PM, Mar J, Comas M, Arrospide A, Castells X.

J Neurol Sci. 2016 Jun 15;365:59-64. doi: 10.1016/j.jns.2016.04.005. Epub 2016 Apr 10.

PMID:
27206876
46.

Characterization and rapid control of a vancomycin-resistant Enterococcus faecium (VREF) outbreak in a renal transplant unit in Spain: The environment matters.

Herrera S, Sorlí L, Pérez-Sáez MJ, Ruiz-Garbajosa P, Barrios C, Plasencia V, Montero M, Terradas R, Crespo M, Castells X, Cantón R, Pascual J, Horcajada JP.

Enferm Infecc Microbiol Clin. 2017 Jan;35(1):5-11. doi: 10.1016/j.eimc.2016.04.002. Epub 2016 May 5.

PMID:
27156245
47.

[Variations in the diagnostic confirmation process between breast cancer mass screening units].

Natal C, Fernández-Somoano A, Torá-Rocamora I, Tardón A, Castells X; en nombre del grupo BELE.

Gac Sanit. 2016 Jul-Aug;30(4):265-71. doi: 10.1016/j.gaceta.2016.03.005. Epub 2016 Apr 29. Spanish.

48.

MutSpec: a Galaxy toolbox for streamlined analyses of somatic mutation spectra in human and mouse cancer genomes.

Ardin M, Cahais V, Castells X, Bouaoun L, Byrnes G, Herceg Z, Zavadil J, Olivier M.

BMC Bioinformatics. 2016 Apr 18;17:170. doi: 10.1186/s12859-016-1011-z.

49.

Cost Attributable to Nosocomial Bacteremia. Analysis According to Microorganism and Antimicrobial Sensitivity in a University Hospital in Barcelona.

Riu M, Chiarello P, Terradas R, Sala M, Garcia-Alzorriz E, Castells X, Grau S, Cots F.

PLoS One. 2016 Apr 7;11(4):e0153076. doi: 10.1371/journal.pone.0153076. eCollection 2016.

50.

Clinical guideline for the treatment of dual pathology in the adult population.

San L, Arranz B, Dual Pathology Clinical Practice Guide EG, Arrojo M, Becoña E, Bernardo M, Caballero L, Castells X, Cunill R, Florez G, Franco MD, Garriga M, Goikolea JM, González-Pinto A, Landabaso M, López A, Martinez-Raga J, Merino A, Paramo M, Rubio G, Safont G, Saiz PA, Solà I, Tirado J, Torrens M, Zorrilla I.

Adicciones. 2016 Mar 2;28(1):3-5. doi: 10.20882/adicciones.784. English, Spanish.

Supplemental Content

Loading ...
Support Center